Free Trial

HC Wainwright's Rating of Rein Therapeutics on 9/22/2025

On September 22, 2025, HC Wainwright updated its outlook on Rein Therapeutics (NASDAQ:RNTX) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
9/24/2025
uniQure N.V. stock logo
QURE
uniQure
Reiterated Rating
9/24/2025
FibroGen, Inc stock logo
FGEN
FibroGen
Reiterated Rating
9/24/2025
Mogo Inc stock logo
MOGO
Mogo
Reiterated Rating
9/24/2025
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
Lower Price Target
9/23/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Reiterated Rating
9/23/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Lower Price Target
More Ratings From HC Wainwright